 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- tilatamig samrotecan (AZD9592) / AstraZeneca
Hanjugator camptothecin platform: Effective, low-toxicity design maximizing antibody functionality and delivering potential best-in-class EGFR/cMet bispecific antibody-drug conjugate (Section 17) - Mar 17, 2026 - Abstract #AACR2026AACR_9057;
This modular design accommodates diverse targets and ADC programs, optimizing dosing regimens and broadening clinical applications. The LPA003-conjugated EGFR/cMet bispecific ADC exhibits a superior therapeutic index, maximizing antibody-mediated signaling blockade, and positions as best-in-class molecule with Investigational New Drug submission anticipated in Q1 2026.
- || tilatamig samrotecan (AZD9592) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Monotherapy, First-in-human: EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) - Aug 7, 2025
P1, N=403, Recruiting, Sponsor: AstraZeneca
The LPA003-conjugated EGFR/cMet bispecific ADC exhibits a superior therapeutic index, maximizing antibody-mediated signaling blockade, and positions as best-in-class molecule with Investigational New Drug submission anticipated in Q1 2026. N=228 --> 403 | Trial completion date: Jan 2026 --> Oct 2027 | Trial primary completion date: Jan 2026 --> Oct 2027
- tilatamig samrotecan (AZD9592) / AstraZeneca
AZD9592, an EGFR/cMET bispecific antibody-drug conjugate (ADC), demonstrates target-dependent efficacy in colorectal cancer (CRC) patient-derived xenograft (PDX) models (Section 18; Poster Board No: 13) - Mar 25, 2025 - Abstract #AACR2025AACR_5428;
AZD9592 demonstrated dose-dependent antitumor activity in CRC PDX models, including KRAS-mutant and KRAS-wildtype tumors. These responses suggest opportunities for clinical development of AZD9592 in CRC and the potential for biomarker-guided patient selection.
- tilatamig samrotecan (AZD9592) / AstraZeneca
Establishing preclinical activity of topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate AZD9592 in patient-derived xenograft (PDX) models of metastatic colorectal cancer (mCRC) in context of irinotecan pretreatment and resistance (Section 18; Poster Board No: 9) - Mar 25, 2025 - Abstract #AACR2025AACR_5424;
AZD9592 was effective in mCRC PDX models that did not respond to irinotecan-based treatment. Ongoing research is evaluating whether multiple doses of AZD9592 can induce resistance in PDX models, and potential resistance mechanisms are being assessed by molecular characterization.
- KA-2886-LD38 / KYinno, Escugen Biotechnology
KA-2886-LD38: a bispecific antibody-drug conjugate (ADC) targeting both EGFR and MET, incorporating a novel linker-payload that inhibits DNA topoisomerase I (Section 34; Poster Board No: 20) - Mar 25, 2025 - Abstract #AACR2025AACR_4134;
KA-2886-LD38 is well-tolerated at doses up to 30 mg/kg in EGFR and MET humanized genetically modified mice, and toxicity studies in monkeys are ongoing. These results suggest that KA-2886-LD38 has remarkable potential in the landscape of anti-EGFR/cMet therapies.
- || tilatamig samrotecan (AZD9592) / AstraZeneca
Enrollment change, Monotherapy, First-in-human: EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) - Feb 4, 2025
P1, N=228, Recruiting, Sponsor: AstraZeneca
These results suggest that KA-2886-LD38 has remarkable potential in the landscape of anti-EGFR/cMet therapies. N=162 --> 228
- || Review, Journal: Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions. (Pubmed Central) - Oct 25, 2024
Other important anti-MET targeted therapies in development include antibody drug conjugates such as telisotuzumab vedotin, REGN5093-M114, and AZD9592 and emibetuzumab, which is a humanized immunoglobulin G4 monoclonal bivalent MET antibody...Future research should focus on developing novel MET antibody drugs and exploring new therapeutic combinations to enhance treatment efficacy and overcome resistance in NSCLC. Refining biomarker-driven approaches to ensure precise patient selection is also critical to optimizing treatment outcomes.
- || tilatamig samrotecan (AZD9592) / AstraZeneca
Enrollment change, Monotherapy, First-in-human: EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) - Mar 28, 2024
P1, N=162, Recruiting, Sponsor: AstraZeneca
Refining biomarker-driven approaches to ensure precise patient selection is also critical to optimizing treatment outcomes. N=108 --> 162
- VBC101-F11 / VelaVigo
VBC101-F11: An innovative EGFR/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors (Section 53) - Mar 5, 2024 - Abstract #AACR2024AACR_2150;
N=108 --> 162 Abstract is embargoed at this time.
- || tilatamig samrotecan (AZD9592) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, First-in-human: EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) - Mar 2, 2024
P1, N=108, Recruiting, Sponsor: AstraZeneca
Abstract is embargoed at this time. Trial completion date: Mar 2025 --> Oct 2025 | Trial primary completion date: Mar 2025 --> Oct 2025
- AZD9592 / AstraZeneca
Maximizing Preclinical Data to Tailor Translational Plans for Bispecific ADC: Lessons From AZD9592, an EGFR-cMET Bispecific ADC () - Aug 9, 2023 - Abstract #ADCUSA2023ADC_USA_186;
Trial completion date: Mar 2025 --> Oct 2025 | Trial primary completion date: Mar 2025 --> Oct 2025 Exploring the characterization of internalization and cytotoxic properties of AZD9592, a bispecific ADC designed to selectively bind EGFR and c-MET on tumor cells and deliver a topoisomerase 1 inhibitor payload; Using in vivo PDX studies to explore relationship of target expression to tumor growth inhibition; Describing pharmacodynamic biomarkers supporting multi-faceted mechanism of action
- AZD9592 / AstraZeneca
EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2209;
P1
Reused with permission. This abstract was accepted and previously presented at the 2023 ASCO Annual Meeting.
- AZD9592 / AstraZeneca
In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a Broad Panel of NSCLC Patient-Derived Xenograft Models (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1992;
These included EGFRwt and EGFRm tumours harbouring varied EGFR mutations; groups with and without prior chemotherapy; and groups with and without prior treatment with ALK, EGFR, and/or cMET TKI. These observations suggest that AZD9592 may provide clinical benefit in areas of unmet need, including in patients previously treated with chemotherapy or targeted agents.
- || tilatamig samrotecan (AZD9592) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, First-in-human: EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) - Jun 15, 2023
P1, N=108, Recruiting, Sponsor: AstraZeneca
These observations suggest that AZD9592 may provide clinical benefit in areas of unmet need, including in patients previously treated with chemotherapy or targeted agents. Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
- AZD9592 / AstraZeneca
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors. (On Demand | Hall A; Poster Bd # 352b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1855;
P1
The study will include sites across the EU, USA, and Asia Pacific; sites in USA and Australia are currently open for enrollment. Clinical trial information: NCT05647122.
- AZD9592 / AstraZeneca
Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate (Room W224 - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_7886;
Collectively, these results support the hypothesized mechanism of action of AZD9592: TOP1i induced tumor cell death due to formation of DNA DSB, and suggest opportunities in the treatment of tumors with a range of molecular features. AZD9592 is currently in a Phase 1 clinical trial in advanced solid malignancies.
- AZD9592 / AstraZeneca
AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond (Room W224 - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_7885;
Plasma pharmacokinetics in cynomolgus monkeys showed an acceptable profile at tolerated doses, in line with other EGFR and cMET directed antibodies. These results demonstrate that AZD9592 has a promising efficacy and safety profile in preclinical models representing diverse opportunities in multiple clinical settings.
- ||| tilatamig samrotecan (AZD9592) / AstraZeneca
Enrollment open, Monotherapy, First-in-human: EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) - Jan 6, 2023
P1, N=108, Recruiting, Sponsor: AstraZeneca
These results demonstrate that AZD9592 has a promising efficacy and safety profile in preclinical models representing diverse opportunities in multiple clinical settings. Not yet recruiting --> Recruiting
- ||| tilatamig samrotecan (AZD9592) / AstraZeneca
New P1 trial, Monotherapy, First-in-human: EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) - Dec 12, 2022
P1, N=108, Not yet recruiting, Sponsor: AstraZeneca